Product warning issued for weight loss drug Belvic: FDA

Taiwan's Food and Drug Administration (FDA) on Friday issued a product warning for the weight loss drug Belviq, after American medical authorities reported on Thursday that clinical trials on the drug's active ingredient, lorcaserin, showed an increased risk of several types of cancer.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)